Traders should closely monitor the upcoming PFS and OS data readout for tovecimig in April 2026, which could be a major catalyst. The expanded pipeline activity and strong cash runway reduce near-term dilution risk, but the increasing R&D spend and lack of revenue may pressure margins until clinical milestones are achieved.
Price Chart
Executive Summary
Compass Therapeutics reported its 2025 financial results and provided a corporate update, highlighting progress in its clinical pipeline, including the upcoming readout of key secondary endpoints (PFS and OS) from the Phase 2/3 COMPANION-002 trial of tovecimig in biliary tract cancer in April 2026. The company also advanced CTX-8371 and CTX-10726 into new trials and expanded its leadership team. Financially, the company reported a wider net loss of $66.5 million in 2025 but ended the year with $209 million in cash, providing a runway into 2028.
Key Financial Metrics
Key Facts
- Tovecimig's Phase 2/3 COMPANION-002 study reached 80% OS event threshold; PFS and OS analyses expected in April 2026.
- CTX-8371 expansion cohorts for TNBC and NSCLC are enrolling; a new cohort for Hodgkin lymphoma will begin shortly.
- FDA cleared IND for CTX-10726; Phase 1 trial to open in Q1 2026.
- Net loss for 2025 was $66.5 million vs. $49.4 million in 2024.
- Cash and marketable securities were $209 million as of December 31, 2025, up from $127 million in 2024, providing runway into 2028.
- R&D expenses increased 32% YoY to $56.0 million, driven by manufacturing costs for tovecimig and CTX-10726.
Financial Impact
Net loss increased by $17.1 million YoY to $66.5 million, while cash position improved by $82 million to $209 million due to a $129 million public offering.
Risk Factors
- Clinical trial results for tovecimig may not meet expectations, leading to a negative stock reaction.
- Continued high R&D spending could erode cash faster than anticipated if additional funding is needed before 2028.
- Delays in clinical development or regulatory setbacks for CTX-8371 or CTX-10726 could impact investor sentiment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (CMPX) — Batch item 1 | 0001171843-26-001336 |
| Document: f8k_030326.htm | press-3250042 |
| Document: 0001171843-26-001336-index-headers.html | 0001171843-26-001336 |
| Document: 0001171843-26-001336-index.html | 0001171843-26-001336 |
| Document: 0001171843-26-001336.txt | 0001171843-26-001336 |
| PRESS-RELEASE Data (Synthetic) | 0001171843-26-001336 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 24, 2026 3d ago | Press Release | $0.7472 | awaiting T+20 | — | $0.7470 (−0.03%) |
Sep 22, 2026 5w ago | 8-K | $1.24 $0.8330 | ▲ +32.82% | ▲ +32.26% | $0.7470 (+39.76%) |
Aug 21, 2026 9w ago | Institutional Cluster | $2.40 $1.90 | ▼ −20.83% | ▼ −20.55% | $0.7470 (−68.88%) |
Aug 6, 2026 11w ago | 8-K | $1.99 $2.37 | ▲ +19.10% | ▲ +18.50% | $0.7470 (−62.46%) |
Aug 6, 2026 11w ago | Press Release | $1.99 $2.37 | ▲ +19.10% | ▲ +18.50% | $0.7470 (−62.46%) |
Jul 17, 2026 14w ago | Press Release | $2.05 $2.25 | ▲ +9.76% | ▲ +5.31% | $0.7470 (−63.56%) |
Jul 1, 2026 16w ago | 8-K | $2.27 $1.94 | ▼ −14.54% | ▼ −14.12% | $0.7470 (−67.09%) |
Jun 11, 2026 19w ago | Institutional Cluster | $2.03 $2.33 | ▲ +14.78% | ▲ +13.00% | $0.7470 (−63.20%) |
May 21, 2026 22w ago | Press Release | $2.07 $2.09 | ▲ +0.72% | ▲ +2.14% | $0.7470 (−63.91%) |
May 5, 2026 25w ago | 8-K | $1.95 $2.08 | ▲ +6.67% | ▲ +1.71% | $0.7470 (−61.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers